BIO B — Bio-Rad Laboratories Share News
0.000.00%
Last trade - 00:00- $9.75bn
- $9.34bn
- $2.58bn
Palantir, Dell slip ahead of S&P 500 inclusion
Newscasts - US Markets Briefing: Wall St bounces as focus shifts to rates outlook
Erie Indemnity gains on inclusion in the S&P 500 index
Dell, Palantir and Erie Indemnity to join S&P 500
Bio Rad Laboratories Inc reports results for the quarter ended in June - Earnings Summary
Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
Brief: Bio-Rad Q2 Adjusted EPS USD 3.11 Vs. IBES Estimate USD 2.01
What to Watch in the Day Ahead - Thursday, August 1
Bio Rad Laboratories Inc expected to post earnings of $2.01 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Carmax, Eli Lilly, Microstrategy
Brief: U.S. Federal Register FDA Announcing Revocation Of Euas Issued To Bio-Rad Laboratories
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Brief: Bio-Rad Q1 Adjusted EPS USD 2.29 Vs. IBES Estimate USD 2.15
What to Watch in the Day Ahead - Tuesday, May 7
Bio Rad Laboratories Inc expected to post earnings of $2.15 a share - Earnings Preview
Brief: Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp
OncoCyte jumps on partnership with Bio-Rad
Brief: Oncocyte And Bio-Rad Partner On Global Launch Of Transplant Assay
Brief: Bio-Rad’S Chief Operating Officer Andrew Last To Retire